AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26802812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (omega-3 PUFAs) for 6 weeks
Number of subjects: 16
Study 25539547 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-calorie diet (NCD) with exercise
Number of subjects: 37
Study 25539547 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet (LCD) with exercise
Number of subjects: 37
Study 22365373 — intervention group
Group type: EXPERIMENTAL
Intervention: Meniett low-pressure generator
Number of subjects: 68
Study 20370447 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 40
Study 20370447 — intervention group
Group type: COMPARATOR
Intervention: Unfractioned Heparin (UFH)
Number of subjects: 40
Study 18413671 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist (GnRHa)
Number of subjects: 13
Study 18413671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 16634346 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 101
Study 16634346 — intervention group
Group type: EXPERIMENTAL
Intervention: Barthel Index
Number of subjects: 101
Study 16634346 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk Control Test
Number of subjects: 101
Study 16634346 — intervention group
Group type: EXPERIMENTAL
Intervention: Motricity Index of arm and leg
Number of subjects: 101
Study 16634346 — intervention group
Group type: EXPERIMENTAL
Intervention: Brunnstrom Fugl‐Meyer stage of leg motor recovery
Number of subjects: 101
Study 16634346 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of intervention
Number of subjects: 101
Study 16634346 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly re-evaluation
Number of subjects: 101
Study 16634346 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent gait (FAC > or = 4)
Number of subjects: 101
Study 14558379 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal management
Number of subjects: 0
Study 14558379 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 11054359 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (1,000 mg IV, 12 hours before procedure)
Number of subjects: 221
Study 11054359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (1,000 mg IV, 3 hours before procedure)
Number of subjects: 221
Study 11054359 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (control group)
Number of subjects: 221
Study 8844478 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 MIU IFN, administered twice per week for 24 weeks
Number of subjects: 36
Study 8844478 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MIU IFN, administered twice per week for 24 weeks
Number of subjects: 36
Study 8844478 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MIU IFN, administered twice per week for 24 weeks
Number of subjects: 36
Study 8844478 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 36
Study 1626962 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled localized heating at 50 degrees C for 30 to 60 seconds
Number of subjects: 29
Study 1626962 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 29
Study 6439714 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific prompt and monetary incentives
Number of subjects: 1133
Study 6439714 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific prompt and increased public health clinic access
Number of subjects: 1133
Study 6439714 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific prompt
Number of subjects: 1133
Study 6439714 — intervention group
Group type: EXPERIMENTAL
Intervention: General prompt
Number of subjects: 1133
Study 6439714 — intervention group
Group type: COMPARATOR
Intervention: Contact control
Number of subjects: 1133
Study 6439714 — intervention group
Group type: COMPARATOR
Intervention: No contact control
Number of subjects: 1133
Study 31372804 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE-clamp runs at RPEGET
Number of subjects: 21
Study 31372804 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE-clamp runs at RPEGET+15%
Number of subjects: 21
Study 31372804 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study 29712564 — intervention group
Group type: EXPERIMENTAL
Intervention: PARTNER model intervention with tailored online training and electronic medical record support for GPs, including referral to the PARTNER Care Support Team (CST), provision of OA educational materials, a leg muscle strengthening program, and access to a weight-loss program.
Number of subjects: 572
Study 29712564 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by control group GPs without additional training.
Number of subjects: 572
Study 26620733 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow maxillary expansion (SME) using quad-helix appliance
Number of subjects: 50
Study 26620733 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) using Hyrax expander
Number of subjects: 50
Study 26620733 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SME and RME
Number of subjects: 50
Study 25150285 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional steering with a 32-contact electrode
Number of subjects: 8
Study 25150285 — intervention group
Group type: COMPARATOR
Intervention: Conventional spherical stimulation
Number of subjects: 8
Study 25150285 — intervention group
Group type: COMPARATOR
Intervention: Monopolar mode with a commercial electrode
Number of subjects: 8
Study 21414131 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-13Zirconium (TiZr) implants
Number of subjects: 91
Study 21414131 — intervention group
Group type: COMPARATOR
Intervention: Titanium Grade IV implants
Number of subjects: 91
Study 20205166 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake of 629 to 1835 mg/day
Number of subjects: 29
Study 20205166 — intervention group
Group type: COMPARATOR
Intervention: Calcium intake of 648 mg/day (boys)
Number of subjects: 29
Study 20205166 — intervention group
Group type: COMPARATOR
Intervention: Calcium intake of 666 mg/day (girls)
Number of subjects: 29
Study 20205166 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium absorption and bone turnover rates measured using double-stable calcium isotope kinetic analysis
Number of subjects: 29
Study 20205166 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake of 1100 mg/day (boys)
Number of subjects: 29
Study 20205166 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake of 970 mg/day (girls)
Number of subjects: 29
Study 17912118 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly(L‐lactide‐co‐glycolide) osteofixation
Number of subjects: 45
Study 17912118 — intervention group
Group type: COMPARATOR
Intervention: Titanium osteofixation
Number of subjects: 45
Study 16047154 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum (homeopathic treatment) for 6 weeks
Number of subjects: 62
Study 16047154 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 62
Study 16047154 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up after treatment
Number of subjects: 62
Study 12452075 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.05 mg/kg) with atropine (0.5 mg)
Number of subjects: 30
Study 12452075 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital sodium (2 mg/kg) with atropine
Number of subjects: 30
Study 10077182 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral and social issues investigation
Number of subjects: 0
Study 7474770 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia (CEDA) using implantable catheterization system 'Periplant'
Number of subjects: 33
Study 7474770 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia (CEDA) using nonimplantable 'Periflex++'
Number of subjects: 33
Study 7474770 — intervention group
Group type: COMPARATOR
Intervention: Control group (33 patients)
Number of subjects: 33
Study 2266671 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin with glucose
Number of subjects: 12
Study 2266671 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 12
Study 2266671 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regimen of insulin with glucose and albuterol
Number of subjects: 12
Study 6102284 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU oil-miscible vitamin A orally
Number of subjects: 114
Study 6102284 — intervention group
Group type: COMPARATOR
Intervention: 100,000 IU water-miscible vitamin A intramuscularly
Number of subjects: 114
Study 31759243 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped classroom intervention
Number of subjects: 200
Study 31759243 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 200
Study 31392484 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic subinguinal varicocelectomy with open-mouth pressure to drain stagnant venous blood
Number of subjects: 100
Study 31392484 — intervention group
Group type: COMPARATOR
Intervention: Routine microscopic subinguinal varicocelectomy
Number of subjects: 100
Study 27740972 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q2W
Number of subjects: 2181
Study 27740972 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg Q2W
Number of subjects: 2181
Study 27740972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2181
Study 27740972 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg/day
Number of subjects: 2181
Study 26518046 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 272
Study 26518046 — intervention group
Group type: COMPARATOR
Intervention: Formula-feeding
Number of subjects: 272
Study 24452729 — intervention group
Group type: EXPERIMENTAL
Intervention: BP-BES (biolimus-eluting stents with biodegradable polymer)
Number of subjects: 34
Study 22421627 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral training (BT) for 20 minutes on weekdays over a 6-week period
Number of subjects: 106
Study 22421627 — intervention group
Group type: COMPARATOR
Intervention: Control training involving the contralesional arm only
Number of subjects: 106
Study 22421627 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral training (BT) for younger participants (age≤68y)
Number of subjects: 106
Study 20644183 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotional and educational intervention program (lecture session, e-mail literature, reminders, personal approach)
Number of subjects: 344
Study 20644183 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 344
Study 20644183 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotional and educational intervention program
Number of subjects: 344
Study 17716826 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 40,000 U once weekly, starting 7-10 days before radiotherapy
Number of subjects: 148
Study 17716826 — intervention group
Group type: COMPARATOR
Intervention: Control (no Epo)
Number of subjects: 148
Study 17716826 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo)
Number of subjects: 148
Study 15818603 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health Court (MHC) clients
Number of subjects: 0
Study 15818603 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 0
Study 12040280 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemoradiotherapy (induction chemotherapy with cisplatin, etoposide, and vinblastine followed by radiotherapy)
Number of subjects: 101
Study 12040280 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 101
Study 12040280 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemoradiotherapy
Number of subjects: 101
Study 10885909 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel + cisplatin (TAXCIS)
Number of subjects: 0
Study 10885909 — intervention group
Group type: COMPARATOR
Intervention: Teniposide + cisplatin (TENCIS)
Number of subjects: 0
Study 7580077 — intervention group
Group type: EXPERIMENTAL
Intervention: Reagent strip testing of urine specimens
Number of subjects: 0
Study 1962593 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene (new antiestrogenic drug)
Number of subjects: 0
Study 1962593 — intervention group
Group type: COMPARATOR
Intervention: Droloxifene (film-coated tablet, tablet, and standard solution)
Number of subjects: 0
Study 6759056 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg tiaprofenic acid daily for 1 week
Number of subjects: 140
Study 6759056 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 week
Number of subjects: 140
Study 31739708 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (1-mA anodal stimulation for 20 minutes)
Number of subjects: 10
Study 31739708 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study 31739708 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 10
Study 29637543 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured physical activity (PA)
Number of subjects: 1635
Study 29637543 — intervention group
Group type: COMPARATOR
Intervention: Health education (HE)
Number of subjects: 1635
Study 26844514 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV) training at 20 Hz, 3 times per week for 5 min each session
Number of subjects: 45
Study 26844514 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback-deprived plus WBV (VFDWBV)
Number of subjects: 45
Study 26844514 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV) training at 20 Hz
Number of subjects: 45
Study 26844514 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 Hz, eyes open)
Number of subjects: 45
Study 24807340 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 160
Study 24807340 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 160
Study 21336631 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem combined with Gluma Desensitizer (RXU‐G)
Number of subjects: 144
Study 21336631 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐Cem combined with Gluma Desensitizer (GCM‐G)
Number of subjects: 144
Study 21336631 — intervention group
Group type: COMPARATOR
Intervention: Panavia21 (PAN)
Number of subjects: 144
Study 21336631 — intervention group
Group type: COMPARATOR
Intervention: Panavia21 combined with Gluma Desensitizer (PAN‐G)
Number of subjects: 144
Study 19233485 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 100 microg once daily, n=166
Number of subjects: 255
Study 19233485 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) 168 microg, n=85
Number of subjects: 255
Study 17846891 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted HIV prevention program
Number of subjects: 100
Study 17846891 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 100
Study 15178656 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micro g of moistened (2 ml of saline) or dry vaginal misoprostol
Number of subjects: 80
Study 15178656 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 80
Study 11965505 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg) once daily with energy restriction of -2.9 MJ/day (-700 kcal/day) for 15 weeks
Number of subjects: 34
Study 11965505 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily with energy restriction of -2.9 MJ/day (-700 kcal/day) for 15 weeks
Number of subjects: 34
Study 11153770 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular myocardial involvement
Number of subjects: 491
Study 11153770 — intervention group
Group type: COMPARATOR
Intervention: No right ventricular myocardial involvement
Number of subjects: 491
Study 11153770 — intervention group
Group type: COMPARATOR
Intervention: Anterior myocardial infarction
Number of subjects: 491
Study 11153770 — intervention group
Group type: COMPARATOR
Intervention: Inferior myocardial infarction
Number of subjects: 491
Study 9781722 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (30 mg/kg) administered by intrabronchial instillation
Number of subjects: 11
Study 9781722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surfactant instilled)
Number of subjects: 11
Study 8162664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg four times a day)
Number of subjects: 36
Study 8162664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 2901612 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous electrical stimulation
Number of subjects: 21
Study 2901612 — intervention group
Group type: COMPARATOR
Intervention: No electrical stimulation (control group)
Number of subjects: 21
Study 8345000 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycosides (gentamicin, tobramycin, netilmicin)
Number of subjects: 0
Study 8345000 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aminoglycosides)
Number of subjects: 0
Study 362821 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation A (Tegretol)
Number of subjects: 4
Study 362821 — intervention group
Group type: COMPARATOR
Intervention: Formulation B (Neurotol)
Number of subjects: 4
Study 362821 — intervention group
Group type: COMPARATOR
Intervention: Experimental preparations C and D
Number of subjects: 4
Study 31100038 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg (NIVO3)
Number of subjects: 274
Study 31100038 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg plus Ipilimumab 1 mg/kg (NIVO3+IPI1)
Number of subjects: 274
Study 31100038 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg plus Ipilimumab 3 mg/kg (NIVO1+IPI3)
Number of subjects: 274
Study 29378651 — intervention group
Group type: EXPERIMENTAL
Intervention: ABvac40
Number of subjects: 24
Study 29378651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26995376 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once‐weekly 2 mg
Number of subjects: 14000
Study 26995376 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 14000
Study 25125339 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and dietary intervention
Number of subjects: 0
Study 25125339 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 22545567 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD, dissociative disorders, rape by an intimate partner, duration of CSA, number of perpetrators of CSA
Number of subjects: 57
Study 22545567 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral prevention interventions
Number of subjects: 57
Study 20649832 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 150
Study 20649832 — intervention group
Group type: COMPARATOR
Intervention: Silver sulphadiazine (SSD)
Number of subjects: 150
Study 17711927 — intervention group
Group type: EXPERIMENTAL
Intervention: BW-ADAPTED-T4 (1.6 microg/kg bw T4)
Number of subjects: 29
Study 17711927 — intervention group
Group type: EXPERIMENTAL
Intervention: BW-ADAPTED-T3T4 (combination of T3 and T4 at a ratio of 1:10)
Number of subjects: 29
Study 17711927 — intervention group
Group type: COMPARATOR
Intervention: EMPIRICAL-T4 (1 +/- 0.05 microg/kg bw)
Number of subjects: 29
Study 15846250 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective stent implantation
Number of subjects: 40
Study 15846250 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty
Number of subjects: 40
Study 15846250 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 40
Study 15846250 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS findings
Number of subjects: 40
Study 12143089 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliance (MAA)
Number of subjects: 21
Study 12143089 — intervention group
Group type: COMPARATOR
Intervention: Placebo appliance
Number of subjects: 21
Study 10546333 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral exposure to one of the shapes for 90 seconds prior to visual stimuli testing (Experiment 1)
Number of subjects: 96
Study 10546333 — intervention group
Group type: EXPERIMENTAL
Intervention: Less side bias group (Experiment 2)
Number of subjects: 96
Study 10546333 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication of Meltzoff and Borton's experiment (Experiment 3)
Number of subjects: 96
Study 7481021 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (sleep doses and N2O)
Number of subjects: 80
Study 7481021 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (10 mg/kg/h intravenous perfusion)
Number of subjects: 80
Study 7481021 — intervention group
Group type: COMPARATOR
Intervention: Thiopental and N2O
Number of subjects: 80
Study 7481021 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrobenzylperidol (90 micrograms/kg) i.m. followed by sleep doses of propofol
Number of subjects: 80
Study 1980654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 600 mg/day
Number of subjects: 45
Study 1980654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 7006617 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 22
Study 7006617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30553512 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight variability (BWV)
Number of subjects: 10251
Study 30553512 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain quartile
Number of subjects: 10251
Study 28616847 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR calls (5 calls over 3 months)
Number of subjects: 878
Study 25621791 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (α2‐adrenergic agonist)
Number of subjects: 18
Study 25621791 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (muscarinic antagonist)
Number of subjects: 18
Study 25621791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 24295013 — intervention group
Group type: EXPERIMENTAL
Intervention: Concave bevel (Group 1)
Number of subjects: 20
Study 24295013 — intervention group
Group type: COMPARATOR
Intervention: Straight bevel (Group 2)
Number of subjects: 20